CADTH Reimbursement Recommendation - Cemiplimab (Libtayo) - Indication: First-line treatment of adult patients with non–small cell lung

Canadian Agency for Drugs and Technologies in Health

Share artifact

Or copy link:

Register Login

If your institution is a member, please log into Canada Commons from a link provided by your institution. This typically involves logging in via a menu managed by your library.

Accessing this content requires a membership

Check your affiliation Start a trial

If your institution is a member, please log into Canada Commons from a link provided by your institution. This typically involves logging in via a menu managed by your library.

Add to list

You have no lists yet

Manage lists

Citation

Health, C., 2022. CADTH Reimbursement Recommendation - Cemiplimab (Libtayo) - Indication: First-line treatment of adult patients with non–small cell lung, Canadian Agency for Drugs and Technologies in Health. Canada. Retrieved from https://canadacommons.ca/artifacts/2476383/cadth-reimbursement-recommendation-cemiplimab-libtayo-indication/3498440/ on 19 Apr 2024. CID: 20.500.12592/2s6xt4.

Download citation (RIS)

Full-page Screenshot

Screenshot of https://coherent-commons.s3.amazonaws.com/artifacts/file/file/f2a1ffdd-fced-412c-8c45-6d1c4aec4fa6.pdf?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIA23B6R4NTCRHS5NZ3%2F20240419%2Fus-east-2%2Fs3%2Faws4_request&X-Amz-Date=20240419T005823Z&X-Amz-Expires=3600&X-Amz-SignedHeaders=host&X-Amz-Signature=c0bd1d20e66748adf6e1a823741fde0d08efe408ec141167d6a70286f6fa9c4f

CADTH Reimbursement Recommendation - Cemiplimab (Libtayo) - Indication: First-line treatment of adult patients with non–small cell lung

Authors